Phaseline

Companies › Dizal Pharmaceuticals

Dizal Pharmaceuticals: clinical trials, targets and expected readouts

6 active drug programs in 40 registered trials: 19 Phase 1, 16 Phase 2, 5 Phase 3; Oncology, Hematology, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DZD8586 (Birelentinib)
Birelentinib; BTK inhibitor
BTKPhase 3Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Immune Thrombocytopenia (ITP); Healthy; Diffuse Large B-Cell LymphomaNov 2026
Sunvozertinib
EGFR Exon20ins inhibitor
EGFRPhase 3Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer; NSCLC; Non Small Cell Lung Cancer …Dec 2026
Golidocitinib
Tyrosine-protein kinase JAK1 inhibitor
JAK1Phase 3Peripheral T-cell Lymphoma; T-cell Lymphomas; Peripheral T Cell Lymphoma; Maintenance Treatment of Peripheral T-cell Lymphoma …Nov 2027
DZD9008
EGFR inhibitor
EGFRPhase 2Non-small Cell Lung Cancer–
DZD6008
EGFR inhibitor
EGFRPhase 1Non Small Cell Lung Cancer; Nonsmall-cell Lung Cancer; Non-Small Cell Lung CancerJun 2027
GW5282–Phase 1Advanced Solid Tumors; T-cell LymphomasDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05712902SunvozertinibPhase 2Non-Small Cell Lung CancerOncologyOct 2022
NCT06276283DZD9008Phase 2Non-small Cell Lung CancerOncologyDec 2025
NCT06295432DZD9008Phase 2Non-small Cell Lung CancerOncologyJun 2026
NCT06295432DZD9008Phase 2Non-small Cell Lung CancerOncologyJun 2026
NCT07888569DZD8586 (Birelentinib)Phase 1HealthyOtherNov 2026
NCT06733051GolidocitinibPhase 2Natural Killer T-cell LymphomaOncologyDec 2026
NCT06855823GolidocitinibPhase 1Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)OncologyDec 2026
NCT03974022SunvozertinibPhase 1Non-Small Cell Lung CancerOncologyDec 2026
NCT06864624SunvozertinibPhase 2NSCLCOncologyDec 2026
NCT07369739GolidocitinibPhase 2LymphohistiocytosisHematologyJan 2027
NCT07117890SunvozertinibPhase 2Non Small Cell Lung CancerOncologyFeb 2027
NCT06969612GolidocitinibPhase 1NSCLC (Advanced Non-small Cell Lung Cancer)OncologyMay 2027
NCT06966154GolidocitinibPhase 1Natural Killer/T-cell LymphomaOncologyMay 2027
NCT07070440DZD6008Phase 1Non Small Cell Lung CancerOncologyJun 2027
NCT07339345GolidocitinibPhase 2Lymphohistiocytosis, HemophagocyticHematologyJun 2027
NCT06630091GolidocitinibPhase 2Peripheral T Cell LymphomaOncologyJul 2027
NCT07294365DZD8586 (Birelentinib)Phase 2Immune Thrombocytopenia (ITP)HematologyJul 2027
NCT07093710GolidocitinibPhase 1Peripheral T Cell LymphomaOncologyAug 2027
NCT06739265GolidocitinibPhase 1Peripheral T-cell LymphomaOncologySep 2027
NCT06539182DZD8586 (Birelentinib)Phase 2Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaOncologySep 2027
NCT06905197DZD6008Phase 1Non Small Cell Lung CancerOncologySep 2027
NCT06813365DZD6008Phase 1Nonsmall-cell Lung CancerOncologyOct 2027
NCT05668988SunvozertinibPhase 3Non-small Cell Lung CancerOncologyOct 2027
NCT06563999SunvozertinibPhase 2Lung Cancer Stage IIIOncologyNov 2027
NCT07234162GolidocitinibPhase 3Peripheral T-cell LymphomaOncologyNov 2027
NCT06195189SunvozertinibPhase 1Non Small Cell Lung CancerOncologyDec 2027
NCT07525466GolidocitinibPhase 1Extranodal NK T Cell LymphomaOncologyMar 2028
NCT07079475DZD6008Phase 1Non-Small Cell Lung CancerOncologyJun 2028
NCT07079475SunvozertinibPhase 1Non-Small Cell Lung CancerOncologyJun 2028
NCT07414758GolidocitinibPhase 3Peripheral T Cell LymphomaOncologySep 2028
NCT07328217GW5282Phase 1Advanced Solid TumorsOncologyDec 2028
NCT07300514GolidocitinibPhase 3Maintenance Treatment of Peripheral T-cell LymphomaOncologyDec 2028
NCT07754890GolidocitinibPhase 1Cutaneous T-cell Lymphoma (CTCL)OncologyDec 2028
NCT07139873DZD8586 (Birelentinib)Phase 3Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaOncologyJan 2029
NCT07380984GolidocitinibPhase 2Natural Killer/T-cell LymphomaOncologyFeb 2029
NCT07496229GolidocitinibPhase 1T-cell LymphomasOncologySep 2029
NCT07496229GW5282Phase 1T-cell LymphomasOncologySep 2029
NCT07154264DZD8586 (Birelentinib)Phase 2Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaOncologyDec 2029
NCT07274761SunvozertinibPhase 2Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung CancerOncologyMay 2030
NCT07059650DZD8586 (Birelentinib)Phase 1Diffuse Large B-Cell LymphomaOncologyOct 2030

Targets

EGFR (3) JAK1 (1) BTK (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Pfizer Betta Pharmaceuticals BeOne Medicines Incyte Eli Lilly

Companies built like this

Jiangsu Alphamab Biopharmaceuticals Nanjing Sanhome Pharmaceutical Jiangsu Aosaikang Pharmaceutical BeBetter Med TransThera Sciences (Nanjing)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.